ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
ALXO Operating Income
Profit from core operations after operating expenses, before interest and taxes.
ALX Oncology Holdings Inc.NASDAQ: ALXO
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$18.97M, compared with -$31.82M a year earlier. Trailing-twelve-month operating income was -$91.17M.
Context
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +27.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.97M+17.6% QoQ
- Last fiscal yearDec 2025
- -$104.02M+27.0% YoY
- LTMMar 2026
- -$91.17M+33.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +40.4% | +100.0% | +59.6 pp |
| 1 year | +27.0% | +100.0% | +73.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (104.02M) USD
- Year-over-year change
- +27.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (104.02M) | +27.0% |
| FY2024 | 2024-12-31 | (142.47M) | +16.3% |
| FY2023 | 2023-12-31 | (170.28M) | -33.6% |
| FY2022 | 2022-12-31 | (127.44M) | -52.5% |
| FY2021 | 2021-12-31 | (83.56M) | — |
Operating Income vs competitors
How ALXO compares with its peers on the latest reported figures
- ALXO's LTM Mar 2026 operating income of -$91.17M is the 2nd highest of the 8 companies compared; the peer median is -$185.25M.
- Its year-over-year change of +33.2% is the highest of 8, against a peer median of -12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$85.86M | +21.8% | — | 38159.1% | |
| LTM Mar 2026 | -$91.17M | +33.2% | — | — | |
| LTM Mar 2026 | -$116.31M | +11.9% | — | — | |
| LTM Mar 2026 | -$148.28M | -6864.7% | — | 345.2% | |
| LTM Mar 2026 | -$185.25M | -584.4% | — | 577.5% | |
| LTM Mar 2026 | -$205.06M | -12.1% | — | — | |
| LTM Mar 2026 | -$242.4M | +2.4% | — | 381.8% | |
| LTM Jun 2026 | -$350.18M | -12.3% | — | 333.5% | |
| Peer median (excluding ALXO) | -$185.25M | -12.1% | — | 381.8% | |
Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 60.17M | 98.4M | 141.8M | 116.37M | 77M |
| Selling, General & Admin | 23.39M | 29.04M | 28.48M | 26.09M | 23.85M |
| Operating Expenses | 83.56M | 127.44M | 170.28M | 142.47M | 104.02M |
| Depreciation & Amortization | 51K | 342K | 836K | 872K | 706K |
| EBITDA | (83.42M) | (122.84M) | (158.4M) | (132.25M) | (99.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.56M) | (127.44M) | (170.28M) | (142.47M) | (104.02M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 91 | 4.28M | 10.65M | 9.37M | 3.96M |
| Interest Expense | 13K | 238K | 1.57M | 1.73M | 1.6M |
| Other Income / Expenses | 71K | 4.02M | 9.47M | 7.62M | 2.33M |
| Income Before Tax | (83.48M) | (123.42M) | (160.81M) | (134.85M) | (101.7M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | 64K | 0 | 0 | 0 |
| Net Income | (83.46M) | (123.48M) | (160.81M) | (134.85M) | (101.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| EPS (Diluted) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| Weighted Avg Shares | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
| Weighted Avg Shares (Diluted) | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
ALX Oncology Holdings Inc.
NASDAQ:ALXO
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.